Neumora Therapeutics, Inc. · NASDAQ:NMRA
Neumora Therapeutics — Corporate Update (January 2026)
21 slides from Neumora Therapeutics's corporate update, January 2026
Slide 1: NMRA-511 Phase 1b Results: Alzheimer's Disease (AD) Agitation
NMRA-511 Phase 1b Results: Alzheimer’s Disease (AD) Agitation January 2026
Slide 2: Important disclosures
Important disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by brin
Slide 3: Our Mission
Our Mission We are focused on redefining neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients 3
Slide 4: Advancing a leading neuroscience pipeline
Advancing a leading neuroscience pipeline PROGRAM INDICATION Target/Mechanism U.S. Prevalence Preclinical Phase 1 Phase 2 Phase 3 Navacaprant Major Depressive Disorder KOR Antagonist 21M Broad pipeline addressing some of the NMRA-511 Agitation in Alzheimer’s Disease most prevalent diseases V1aR Anta
Slide 5: Alzheimer's disease agitation represents large market opportunity with significant unmet need
Alzheimer’s disease agitation represents large market opportunity with significant unmet need Alzheimer’s disease agitation is a large and Anxiety is a key underlying driver of growing health burden aggression and irritability in dementia3 Millions currently living with AD; prevalence expected to in
Slide 6: Significant opportunity for a product with a differentiated benefit/risk profile
Significant opportunity for a product with a differentiated benefit/risk profile Simplified market segmentation and opportunities There is an unmet medical need for therapies that reduce agitation with improved tolerability and safety profiles3,4 Safety AD agitation associated with: Mild side-effect
Slide 7: NMRA-511 demonstrates positive signal in Phase 1b; potential to treat unmet need
NMRA-511 demonstrates positive signal in Phase 1b; potential to treat unmet need Simplified market segmentation and opportunities NMRA-511 Phase 1b key takeaways Safety • Well tolerated, with potential Mild for higher dosing side-effects Total population Elevated anxiety sub-population • CMAI effect
Slide 8: Vasopressin/V1a receptor (V1aR) mediates anxiety-related behaviors
Vasopressin/V1a receptor (V1aR) mediates anxiety-related behaviors Robust preclinical data supports V1aR inhibition V1a antagonists and vasopressin modulate for treating anxiety in rodents anxiety and stress related behaviors in humans • V1a knock-out1 or reduction by siRNA2 drives reduced anxiety b
Slide 9: NMRA-511 reduced anxiety-related behaviors in a preclinical human threat test
NMRA-511 reduced anxiety-related behaviors in a preclinical human threat test Human threat test induces anxiety NMRA-511 reduces behavioral NMRA-511 does not reduce in marmosets1 response to threat locomotor activity 20 40 15 30 ** ** Postures (#) Jumps (#) 10 20 ** 5 10 0 0 V P1 0 0 0 0. 1. 1 1 1 3
Slide 10: Study to evaluate the effects of NMRA-511 among healthy elderly and adults with agitation
Study to evaluate the effects of NMRA-511 among healthy elderly and adults with agitation associated with dementia due to Alzheimer's disease Part A: 2-Week Evaluation Period Enrolling Part B: 8-Week Evaluation Period Enrolling People Healthy Elderly Participants with Alzheimer’s Disease Agitation (
Slide 11: Demographics and baseline characteristics
Demographics and baseline characteristics NMRA-511 Placebo n=40 n=40 Mean age 71.8 72.7 Sex, n (%) Male 18 (45.0%) 15 (37.5%) Female 22 (55.0%) 25 (62.5%) Race, n (%) White 27 (67.5%) 30 (75.0%) Black 10 (25.0%) 9 (22.5%) Asian 2 (5.0%) 0 Other 1 (2.5%) 1 (2.5%) CMAI Total Score Mean (SD) 68.2 (14.7
Slide 12: NMRA-511 demonstrated clinically meaningful reduction in CMAI total score and CMAI aggression sub-score
NMRA-511 demonstrated clinically meaningful reduction in CMAI total score and CMAI aggression sub-score NMRA-511 demonstrated a 15.7-point reduction in CMAI CMAI aggression sub-score results suggest improvement total score at Week 8 on clinically relevant symptoms of AD agitation CMAI Total Score Ch
Slide 13: NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in patients with elevated anxiety
NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in patients with elevated anxiety CMAI Total Score Change from Baseline Mean Change in CMAI Sub-Scores at Week 8 (pre-specified elevated anxiety sub-population) (pre-specified elevated anxiety sub-population) Physically non-
Slide 14: Favorable tolerability and safety profile demonstrated
Favorable tolerability and safety profile demonstrated NMRA-511 was safe and generally well tolerated • TEAEs were typically mild to moderate in severity TEAEs Incidence Placebo NMRA-511 (≥5% in either treatment group) n=40 n=40 • Low treatment Preferred Terms n (%) n (%) discontinuations due to Nas
Slide 15: NMRA-511 demonstrates positive signal in Phase 1b; potential to treat unmet need
NMRA-511 demonstrates positive signal in Phase 1b; potential to treat unmet need Simplified market segmentation and opportunities NMRA-511 Phase 1b key takeaways Safety • Well tolerated, with potential Mild for higher dosing side-effects Total population Elevated anxiety sub-population • CMAI effect
Slide 16: Key takeaways: Study met goal to identify signal for NMRA-511; Planned next steps
Key takeaways: Study met goal to identify signal for NMRA-511 Planned next steps 1 2 3 Enable higher dosing: Transition BID to QD Initiate Phase 2/3 dose initiate multiple formulation: Switch to ranging study ascending dose QD extended-release extension in 2026 formulation in 2026, strengthening IP
Slide 17: Q&A hosted by
Q&A HOSTED BY Helen Rubinstein Paul Berns Joshua Pinto, Ph.D. VP, Investor Relations Chief Executive Officer President and Communications Nick Brandon, Ph.D. Bill Aurora, Pharm.D. Chief Scientific Officer Chief Operating & Development Officer 17
Slide 18: Appendix
Appendix 18
Slide 19: NMRA-511 was safe and well-tolerated in healthy adults and healthy elderly participants
NMRA-511 was safe and well-tolerated in healthy adults and healthy elderly participants Dose selected for Phase 1b to maximize receptor Phase 1 PK profile occupancy over 24 hours Healthy Adults 40 mg QD in healthy adults compared to 20 mg BID in healthy elderly participants Plasma Concentration of P
Slide 20: Rexulti CMAI sub-scale data
Rexulti CMAI sub-scale data 20 Pulled from RexultiHCP.com: https://www.rexultihcp.com/aad/efficacy#agitated-behaviors-CMAI
Slide 21: Neumora
Y) Neumora
Neumora Therapeutics — Corporate Update (January 2026) on 6ix